Australia: High Court invalidates BRCA1 gene patent and casts doubt on patentability of isolated genes

Last Updated: 20 October 2015
Article by Louise Dumbrell and Rohan Sridhar

Background and Decision

The High Court of Australia has unanimously invalidated a patent, owned by Myriad Genetics, which related to the BRCA1 gene. The BRCA1 gene, and associated protein, are involved in repair of DNA in some human cells. In the 1990s, Myriad Genetics identified the location of the BRCA1 gene within the human genome, and mutations (variations in the gene's sequence) which increased the susceptibility of the patient to breast and ovarian cancer. Myriad Genetics' patent, broadly, included claims to isolated DNA (i.e. removed from the cell, and dissociated from the cellular proteins which bind to DNA) with these mutations. The patent granted Myriad Genetics the sole right to isolate the BRCA1 gene for the purposes of genetic testing.

The case only considered whether the claims related to a "manner of manufacture" and were therefore patentable subject matter. The High Court has overturned previous Federal Court, and Full Federal Court, decisions that found that they did. The High Court's decision has cast significant doubt on the validity of gene patents in general, although the work of the Human Genome Project has largely rendered such patents obsolete.

The High Court issued three separate judgments on the patent in issue, each of which provides substantially different reasoning for the invalidity of the patent. The judgment of the Chief Justice and Justices Kiefel, Bell and Keane (majority judgment) provides a substantial revision of the formulation of the test to determine whether an invention relates to a manner of manufacture, for the first time since the decision in National Research Development Corporation v Commissioner of Patents (NRDC) was handed down in 1959. As recently as December 2013, the High Court had specifically upheld the NRDC test in relation to methods of treatment of humans in the Apotex v Sanofi Aventis case.

What it means:

  • The patent in issue expired in 2014. Therefore there is unlikely to be substantive change in the cost of genetic testing for BRCA1. Since around 2010, Myriad Genetics' local licensee had stopped enforcing its exclusive rights, and indeed Myriad Genetics made an offer to voluntarily surrender the patent.
  • This decision may be seen as invalidating many patents which cover isolated genetic material. Products produced from the isolated genetic materials may still be patentable. For example, claim 4 of the patent related to a probe comprising isolated DNA. The validity of the claim was not in dispute, and at least one judge referred to it positively.
  • The NRDC test, for what constitutes a manner of manufacture, of an "artificially created state of affairs of economic significance" is not sufficient to determine patentability for products which fall outside the established boundaries of patentable subject matter. In new fields of invention, the test has been substantially changed into a form which provides, arguably, less clarity as to what represents patentable subject matter. The majority of the Court articulated a test which requires heavy emphasis on policy considerations when determining the patentability of novel categories of inventions.
  • The Court passed the onus of determining patentability of isolated genes to the legislature. Accordingly the Commonwealth Parliament will need to consider whether to legislate to enable the protection of isolated genes or nucleotides. The Parliament has previously declined opportunities to expressly exclude these products as patentable subject matter against the backdrop of the continued granting of patents by the Patent Office. However, given the strong commentary against gene patents by now Prime Minister Malcolm Turnbull in 2010,1 and the public outcry regarding the claims in dispute, it seems unlikely that the Commonwealth will legislate specifically in favour of gene patenting. The Court's approach on this issue is in marked contrast with the Court's usual position of adopting a broad definition of manner of manufacture and attributing to Parliament the role of constraining it. In this case, the High Court has reversed the roles, and in doing so adopted what appears on its face to be a quasi-legislative approach to questions of patentable subject matter.
  • It is unclear the extent to which this decision will impact upon inventions other than isolated DNA. Given the majority of the Court focused heavily on policy considerations, it is possible that the scope of the decision may prove not to be confined to isolated DNA. The comments of Justice Gordon regarding the delineation of the class of chemical compounds may cause concerns for patent holders in areas such as chemicals which routinely use "Markush formulas" in patent specifications.
  • The reasoning of Gageler and Nettle JJ which introduced a concept of inventiveness into the test for manner of manufacture potentially undercuts the existing, distinct statutory requirements of inventive step and novelty which were not included in the subject matter of this case.
  • Several Judges in the High Court decided that the act of isolating DNA from the human cell did not change its substantive nature as it existed within the cell. They considered that it was the information carried by the DNA that was of critical importance rather than the product which carried it. This assessment led to a conclusion in direct conflict with the decision of all 6 Justices in the Federal Court, who concluded that since the act of isolation fundamentally changed the very nature of the nucleic acid an artificially created state of affairs resulted. The conclusion on the nature of isolated DNA reached by the High Court suggests that the Court could have maintained and applied the standing NRDC test and concluded that the isolated genetic material was not a manner of manufacture as it was not an "artificially created state of affairs".
  • The Court made several comments regarding the chilling effect a gene patent might have on innovation and research in Australia but largely failed to consider the opposite position. Without appropriate patent protection in Australia, there is a very real possibility of a loss of commercial research in these areas. It should be noted that the decision places Australia's patent protection of genes in direct conflict with many major overseas trading partners, such as the European Union, which expressly permits gene patents. The United States is the major exception to this; the US Supreme Court decision on related patents also held that gene sequences were not patentable.


1 Humanity fights for ownership of its soul , The Age

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions